title: MDR1 gene expression in chronic lymphocytic leukemia.
abstract: In order to assess the clinical role of the MDR1 gene in chronic lymphocytic leukemia (CLL), we determined its expression in the leukemic cells of 39 patients with CLL and compared this with other clinical and laboratory parameters. MDR1 RNA expression was detected in 29 patients. MDR1 RNA transcripts were independent of age, treatment status of the patients and the clinical stage of CLL, but correlated with the white blood cell count and MDR2 RNA transcripts. Expression of the tumor suppressor gene p53 was found in 30 out of 37 patients and was associated with MDR1 RNA expression (P < 0.001). Immunocytochemistry using the monoclonal antibody C219 was performed in 38 patients, and in 28 cases, more than 5% of the leukemic cells were found to express cell surface P-glycoprotein. P-glycoprotein expression correlated with the expression of MDR1 RNA (P = 0.048).
authors.affiliation: Clinic for Internal Medicine I, University of Vienna Medical School, Austria.
authors.forename: J
authors.initials: J
authors.lastname: Wallner
authors.forename: H
authors.initials: H
authors.lastname: Gisslinger
authors.forename: B
authors.initials: B
authors.lastname: Gisslinger
authors.forename: A
authors.initials: A
authors.lastname: Gsur
authors.forename: M
authors.initials: M
authors.lastname: Götzl
authors.forename: S
authors.initials: S
authors.lastname: Zöchbauer
authors.forename: R
authors.initials: R
authors.lastname: Pirker
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000494:pharmacology; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D002352:Carrier Proteins / Q000096:biosynthesis / Q000235:genetics*; D002699:Chlorambucil / Q000008:administration & dosage / Q000494:pharmacology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D016158:Genes, p53; D006801:Humans; D007124:Immunoenzyme Techniques; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D012334:RNA, Neoplasm / Q000096:biosynthesis / Q000235:genetics; D014750:Vincristine / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000305:Adrenal Cortex Hormones; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D002699:Chlorambucil; D014750:Vincristine; D003520:Cyclophosphamide; C003726:trofosfamide; D011241:Prednisone